早期肺癌立体定向消融放疗后放射性肺炎的临床与剂量学预测因素:英国最大队列分析
该研究回顾性分析了英国单中心2009年5月至2018年8月接受肺立体定向消融放疗(SABR)的1266例早期肺癌患者,中位随访56个月。结果显示6.7%患者发生≥2级放射性肺炎,仅0.4%为3级。单因素分析中下叶肿瘤位置、较大肿瘤尺寸、PTV、平均肺剂量、肺V20Gy和V12.5Gy与≥2级放射性肺炎显著相关,多因素分析仅平均肺剂量为独立预测因素。
要点
- SABR后≥2级放射性肺炎发生率为6.7%,3级仅0.4%。
- 多因素分析仅平均肺剂量与≥2级放射性肺炎独立相关。
- 下叶肿瘤、较大肿瘤尺寸、PTV、肺V20和V12.5在单因素分析中显著。
核心结论
- SABR治疗导致3级放射性肺炎发生率很低,下叶肿瘤位置、较大肿瘤尺寸、PTV、平均肺剂量、V20和V12.5为症状性放射性肺炎的显著预测因素。
研究设计与样本
- 回顾性队列研究,纳入英国单中心2009年5月至2018年8月接受肺SABR的1266例早期肺癌患者,中位年龄75岁,52.6%为女性,中位随访56个月。
主要发现
- 单因素分析中下叶肿瘤位置、较大肿瘤尺寸、PTV、平均肺剂量、肺V20Gy和V12.5Gy与≥2级放射性肺炎显著相关。
- 多因素分析仅平均肺剂量与≥2级放射性肺炎独立相关。
- ROC曲线分析显示肿瘤尺寸、PTV、平均肺剂量、V20和V12.5的最佳诊断阈值分别为22.5 mm(AUC-0.565)、27.15 cc(AUC-0.58)、3.7 Gy(AUC-0.633)、4.6%(AUC-0.597)、9.5%(AUC-0.616)。
- 高于ROC阈值的患者≥2级放射性肺炎发生率显著增高。
关键数值与推荐
- 65%患者接受55 Gy分5次放疗。
- 中位肿瘤尺寸20 mm(范围4-63 mm),中位PTV 30.3 cc。
- 中位R100、R50和D2cm分别为1.1、5.6和32.8 Gy。
- 中位平均肺剂量、V20和V12.5分别为3.9 Gy、5%和9.3%。
临床怎么用
- 对于早期肺癌SABR患者,应关注平均肺剂量以预测症状性放射性肺炎风险。
- 肿瘤位于下叶、尺寸较大、PTV较大或肺V20、V12.5较高者需警惕≥2级放射性肺炎。
- 可参考ROC阈值(平均肺剂量3.7 Gy、V20 4.6%、V12.5 9.5%等)识别高风险患者。
局限性
- 回顾性研究,放射性肺炎分级基于临床和影像信息回顾性评定。
- 仅31.8%患者有组织学诊断,其余基于影像学诊断。
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic Ablative Radiotherapy (SABR) is the standard treatment for early-stage medically inoperable lung cancer. Predictors of radiation pneumonitis (RP) in patients treated with SABR are poorly defined. In this study, we investigate clinical and dosimetric parameters, which can predict symptomatic RP in early-stage lung cancer patients treated with SABR. MATERIALS AND METHODS: Patients treated with lung SABR between May 2009 and August 2018, in a single United Kingdom (UK) radiotherapy center were included. The patient's baseline characteristics, treatment details, and toxicity were retrieved from the electronic medical record. Dosimetric data was extracted from Xio and Monaco treatment planning systems. Patients were treated according to the UK SABR consortium guidelines. RP was graded retrospectively using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, based on available clinical and imaging information. Univariate and multivariate binary logistic regression was performed to determine predictive factors for grade ≥ 2 radiation pneumonitis, using Statistical Package for the Social Sciences (SPSS) statistics version 21 software. The goodness of fit was assessed using the Hosmer and Lemeshow test. The optimal diagnostic threshold was tested using the Receiver operating characteristics (ROC) curve. The chi-square test was carried out to test the different risk factors against the likelihood of developing grade ≥ 2 pneumonitis. RESULTS: A total of 1266 patients included in the analysis. The median age of patients was 75 years. Six hundred sixty-six patients (52.6%) were female. Median follow up was 56 months. Sixty-five percent of patients received 55 Gy in 5 fractions. Forty-three percent of patients had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 and 16.2% had PS of 3. The Median Charlson comorbidity index was 6 (range 2-11). Median Standardized Uptake Value (SUV) max of the tumor was 6.5. Four hundred two patients (31.8%) had confirmed histological diagnosis; other patients were treated based on a radiological diagnosis. The median tumor size was 20 mm (range 4 mm-63 mm). Median Planning Target Volume (PTV) was 30.3 cc. Median values of R100, R50, and D2cm were 1.1, 5.6, 32.8 Gy. The median value of mean lung dose, V20, and V12.5 were 3.9 Gy, 5 %and 9.3% respectively. Eighty-five (6.7%) patients developed symptomatic RP (grade ≥ 2) with only 5(0.4%) developing grade 3 RP. Five percent of patients developed rib fractures but only 28% of these were symptomatic. On univariate analysis lower lobe tumor location, larger tumor size, PTV, mean lung dose, lung V20Gy, and V12.5 Gy were significantly associated with grade ≥ 2 RP. On multivariate analysis, only mean lung dose was associated with grade ≥ 2 pneumonitis. ROC curve analysis showed optimal diagnostic threshold for tumour size, PTV, mean lung dose, V20 and V12.5; are 22.5 mm ((Area Under Curve (AUC)-0.565)), 27.15 cc (AUC-0.58), 3.7 Gy (AUC-0.633), 4.6% (AUC-0.597), 9.5% (AUC-0.616). The incidence of ≥grade 2 RP was significantly high for values higher than the ROC threshold. CONCLUSION: SABR treatment resulted in a very low rate of grade 3 pneumonitis. Lower lobe tumor location, larger tumor size, PTV, mean lung dose, V20, and V12.5 were found to be significant predictors of symptomatic radiation pneumonitis.
引用
- Saha A, Beasley M, Hatton N, et al. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients. Radiother Oncol. 2020. PMID: 33333139. doi:10.1016/j.radonc.2020.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。